Cargando…
Antibody-removal therapies for de novo DSA in pediatric intestinal recipients: Why, when, and how? A single-center experience
BACKGROUND: Donor-specific anti-HLA antibodies (DSA) impact negatively on the outcome of intestinal grafts. Although the use of antibody-removal therapies (ART) is becoming more frequent in the last few years, issues regarding their timing and effectiveness remain under discussion. METHODS: In the p...
Autores principales: | Lasa-Lázaro, María, Ramos-Boluda, Esther, Mancebo, Esther, Castro-Panete, María José, González-Sacristán, Rocío, Serradilla, Javier, Andrés-Moreno, Ane Miren, Hernández-Oliveros, Francisco, Paz-Artal, Estela, Talayero, Paloma |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932897/ https://www.ncbi.nlm.nih.gov/pubmed/36819192 http://dx.doi.org/10.3389/fped.2022.1074577 |
Ejemplares similares
-
Perforin gene variant A91V in young patients with severe COVID-19
por: Cabrera-Marante, Oscar, et al.
Publicado: (2020) -
Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study
por: Matignon, Marie, et al.
Publicado: (2017) -
Differential Treatment Effects for Renal Transplant Recipients With DSA-Positive or DSA-Negative Antibody-Mediated Rejection
por: Koslik, Marius Andreas, et al.
Publicado: (2022) -
Effect of SARS-CoV-2 Infection on Anti-HLA Antibodies and De Novo DSA Incidence in Lung Transplant Recipients
por: Zajacova, A., et al.
Publicado: (2022) -
IL-6–based mortality risk model for hospitalized patients with COVID-19
por: Laguna-Goya, Rocio, et al.
Publicado: (2020)